Microbio Co., Ltd.TPEX: 4128

Microbio receives a R.O.C. patent on the new drug MS-20 (CHEMO YOUNG).

· Issued by Microbio Co., Ltd.
Close
Today's Information
Provided by: MICROBIO CO.,LTD.
SEQ_NO1Date of announcement2022/06/01Time of announcement16:25:38
Subject
 Microbio Co.,LTD. receives a R.O.C. patent on
the new drug MS-20 (CHEMO YOUNG).
Date of events2022/06/01To which item it meetsparagraph 53
Statement
1.Date of occurrence of the event:2022/06/01
2.Company name:Microbio Co.,LTD.
3.Relationship to the Company (please enter "head office" or
  "subsidiaries"):Head office
4.Reciprocal shareholding ratios:NA
5.Cause of occurrence:The Company has been informed by the patent agency
that the new drug: MS-20 has been granted a Republic of China patent titled
"COMBINED CANCER THERAPY WITH IMMUNE CHECKPOINT MODULATORS AND FERMENTATION
PRODUCTS BY SYMBIOTIC MICROBIOTA" under patent number I762473.
6.Countermeasures:NA
7.Any other matters that need to be specified:
(1)The patents from the U.S., the Republic of China, Japan, the People's
   Republicof China, the Hong Kong Special Administrative Region, Europe,
   Korea,Indonesia, India, Canada, Singapore, Malaysia, United Arab
   Emirates and Brazil have been subsequently granted on the new drug,
   Chemoyoung (MS-20).
(2)This patent presents a combination therapy with Chemoyoung (MS-20) and
   anti-PD1 antibody to enhance the anti-cancer efficacy of immune checkpoint
   modulators.

Microbio Co., Ltd. on 6ix

Story so far

Earlier from Microbio

Later from Microbio

All Microbio news releases